Laborie Medical Technologies Corp., a global leader in medical technology, today announced the appointment of Chris Smith as Chief Executive Officer, effective September 22, 2025. Smith succeeds Michael Frazzette, who announced his retirement last month.

Chris Smith brings over three decades of executive leadership experience in the healthcare and medical technology sectors. He has previously served as CEO of NeoGenomics Laboratories, Ortho Clinical Diagnostics, and Cochlear Limited, where he led transformative growth and innovation. Smith has also held several board positions across both private and public companies.

"The Laborie Board of Directors thanks Mike for his outstanding contributions to Laborie during his tenure as CEO," said David Perez, Chair of the Board. "We look forward to working with Chris as Laborie's new CEO, and we are confident that his experience and expertise make him the right leader to guide Laborie's next chapter."

"We look forward to working with Mike in his new capacity and thank him for his exceptional leadership of Laborie and partnership with Patricia Industries over the past eight years," said Yuriy Prilutskiy, Co-Head of Patricia Industries. "During this time, Laborie has achieved significant growth, expanded its product portfolio and global presence, and fostered an innovative, high-performance culture. We are excited to partner with Chris to build on this momentum, and are confident that his leadership style, business acumen, and deep expertise in medical technology will position him to lead Laborie with impact and vision."

Smith has served on Laborie's Board of Directors since 2023, providing strategic counsel during a period of significant expansion. His familiarity with the company's mission and operations positions him to seamlessly transition into the CEO role.